Fig. 4E illustrates that PFDN6L expression was elevated in the overexpression group compared with the control group. Moreover, Ki67 expression was markedly reduced in the PFDN6L overexpression group compared with the control group.Additionally, results showed that CD133 and CD44 expression levels were reduced in the PFDN6L overexpression group relative to the control group (Fig. 4E,F). These findings suggest that the overexpression of PFDN6L can inhibit the tumorigenicity and growth of HCC cells in vivo. This evidence concerns the gene CCDC30 and hepatocellular carcinoma.